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Summary: In order to ascertain the distribution of aluminium in normal and occupationally exposed sera, size-
exclusion chromatography using two fractionation techniques was applied: gel filtration (Sephadex G-100 SF) and
HPLC (TSK G4000 SW). For each of the techniques, protein profiles obtained for control and exposed sera did not
differ and aluminium was found to be associated with the same fractions.
Ultrafiltration of sera using Centricon concentrators having a nominal cut-off of Mr = 10000 confirmed the pres-
ence of high molecular mass and ultrafiltrable low molecular mass aluminium complexes in serum.
Absolute quantitation and relative distribution of aluminium in the aforementioned complexes in original and spiked
sera were determined using Zeeman atomic absorption spectrometry. It was found that the relative distribution of
aluminium between high molecular mass and low molecular mass fractions was 79.1% and 19.6% in controls,
compared to 91.3% and 8.7% in exposed sera, which is highly significant for both high molecular mass (p < 0.026)
and low molecular mass (p < 0.004). After spiking both control and exposed sera with 400 g/l of Al, the distribu-
tion changed. The percentage of the aluminium bound to high molecular mass increased from 79.1% to 98.9% for
controls, and from 91.3% to 98.4% for exposed sera, confirming the affinity of high molecular mass proteins,
especially transferrin for aluminium. On the other hand, the percentage of aluminium bound to low molecular mass
decreased after spiking to 1.12% for controls and to 1.6% for exposed sera. These differences were not statistically
significant. This suggests that at high concentrations of total aluminium in serum, the percentage of the aluminium
bound to the low molecular mass is lower but the absolute quantity of aluminium circulating as the low molecular
mass complex is increased. This low molecular mass aluminium complex is thought to play an important role in
intracellular accumulation of aluminium.
An analytical method is proposed for the speciation of aluminium in serum.
Introduction ciated with patients on long-term haemodialysis causing
Aluminium is considered to be a detrimental element to dialysis-related diseases such as vitamin D-resistant
living systems. Studies with aluminium provide a very osteomalacia «^ dialysis encephalopathy (1-3).
good example of how a detrimental metal ion can make There is also evidence of toxic effects of aluminium in
use of the endogenous ligands, in its absorption, trans- occupationally exposed subjects (4-5). This is an area
port, and availability so as to finally exert its toxic ef- of particular concern because chronic occupational ex-
fects on the target organs. Successful competition for the posure to aluminium is very common,
binding sites on different ligands, normally available to
 In contrast to haemodialysis patients with high alumin-
carry metal ions which have similar properties, will be
 ium loading where the serum aluminium concentration
the target of such an interaction. Aluminium has been
 can be eievated, the concentrations of aluminium in se-
found to have the potential to cause toxicity to the rum of occupationally exposed subjects are usually well
central nervous system, skeletal and haematopoietic sys-
 within the acceptable normal levels. Hence, the use of
terns. Its accumulation in humans can produce a number aluminium concentrations as an index of aluminium
of disorders. Aluminium toxicity has mainly been asso- loading remains speculative (6-7).
Identification of metal ions and their binding fractions
') Parts of this study were presented at the 36th Congress of in biological fluids can elucidate some of the underlying
the Federation of South African Societies of Pathology (FSASP), mechanisms of excess or deficiency of metal ions, as
held at the Karos Kruger Lodge, Mpumalanga, South Africa, ,, , . . . „ , , , , . _
29th June-3rd July 1996, and abstracted in the Conference Pro- wel1 as their toxicity. Even though the mechanisms of
ceedings. metal toxicity are mostly not known, it has been pro-
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posed that toxic metal bioavailability, and hence toxicity,
depends on the physiochemical form of the metal before
it enters the body to be transported within biological
fluids and tissues. Knowledge in this field is still very
limited not only for aluminium but also for other metals,
especially if inhalation is the route of exposure.
Speciation studies to elucidate the distribution of alu-
minium among the different serum components are
therefore of particular importance. Experimental and
computer simulation studies (8) indicate that both low
molecular mass and high molecular mass ligands are in-
volved in the transport and bioavailability of aluminium.
Day et al. studied the gastrointestinal absorption of alu-
minium in humans under physiologically normal condi-
tions of aluminium loading using the 26A1 tracer and
high energy accelerator mass spectrometry (9). This
technique is highly specialised and not easily accessible.
The highest plasma concentration of 26A1 was found in
the sample obtained 6 hours post-ingestion. Ninety five
percent of the absorbed aluminium was associated with
high molecular mass species in plasma, of which 80%
represented aluminium bound to transferrin, 10% bound
to albumin, and 5% bound to other high molecular mass
species. The non-protein low molecular mass fraction
was shown to contain the remaining 5% of aluminium.
Aluminium absorption is possibly facilitated by its affin-
ity for the iron-transporting protein transferrin, the alu-
minium-transferrin complex being endocytosed by sus-
ceptible brain cells (10).
The binding of aluminium to transferrin and to other
ligands was also investigated by Fatemi et al., who con-
firmed that aluminium can bind to transferrin (11). Fa-
temi et al. also showed that aluminium binds to transfer-
rin with less affinity than Fe3+ (12). This may ex-
plain why aluminium is released from transferrin much
faster than iron. This led to the suggestion that this
binding may be important if A13+ uptake into cells is
largely a result of receptor-mediated endocytosis of the
(Al3+)2-transferrin-complex (13).
Research in this field is hindered by the complexity of
the analytical determinations of aluminium in biological
fluids. This complexity becomes even more pronounced
if speciation studies are called for.
Several workers have investigated aluminium distribu-
tion in serum of normal and uraemic subjects using gel
filtration chromatography and ultrafiltration techniques;
the results published are very controversial and far from
reaching a consensus.
Trapp used Sephadex G-200 and G-50 to identify alu-
minium bindings in serum and found that the major ac-
ceptors of aluminium added to serum in vitro were albu-
min and transferrin. No bindings by low molecular mass
constituents were observed (14). Bertholfet al. used a
cation exchange resin, chelex, to quantitatively study
aluminium binding to human serum albumin and
transferrin. Both albumin and transferrin were found to
produce linear Scatchard plots of aluminium binding
data over the aluminium and protein concentration
ranges found in humans (15). Favarato et al. used TSK-
Gel HW 55S for determining the distribution of alumin-
ium in human serum from both normal and occupa-
tionally exposed subjects. They found aluminium to be
bound in a stable complex form to a protein fraction
which they called albindin (16).
Perez Parajon et al. used two different ultrafiltration
techniques to quantify ultrafiltrable aluminium fractions
(17). By using a standard ultrafiltration method they
found that the ultrafiltrable fraction of aluminium
amounted to 20.8—47.9% of the total concentration of
aluminium in normal serum, while the non-filtrable alu-
minium amounted to 91.7—99.2%. This result indicates
that there was a contamination problem. On the other
hand, when using the ultramicrofiltration technique the
ultrafiltrable aluminium amounted to only 8.3%.
Van Ginkel et al. used the gel filtration technique and
found that 23% of total aluminium co-eluted with citrate
and only 21 % was found in the transferrin peak (18). Their
experiment did not confirm earlier reports by King et al.
that the ultrafiltrable aluminium fraction increased as the
total serum aluminium concentration increased (19).
Recent studies by Wrobel et al., using ultramicrofiltra-
tion membranes, have shown that the natural relative
distribution of ultrafiltrable aluminium in serum is a
constant factor of 11% and this distribution does not
seem to be influenced by the total serum aluminium
concentration, the particular renal pathology of the pa-
tients, or even kidney transplantation (20).
Aluminium is an ubiquitous element and all procedures
should be devised in such a manner as to eliminate or
at least minimise and control the risk of external con-
tamination. All procedures must be performed in a labo-
ratory specialising in trace metal assays using very sen-
sitive instrumentation. The detailed procedures to mini-
mise contamination as described by Perez Parajon et
al., Van Landeghem et al. and Wrobel et al. are examples
of correct analytical procedures employed to control
contamination risk (17, 21, 22).
The main objective of our study was to characterise the
distribution of aluminium in serum of control and occu-
pationally exposed subjects, following Sephadex G-100
SF and HPLC gel permeation profiling. Subjects were
occupationally exposed to aluminium dust, by inhala-
tion, in potrooms of a primary aluminium smelter.
In addition, we studied the speciation of aluminium be-
tween high molecular mass and low molecular mass se-
rum fractions following ultrafiltration.
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Moreover, the Zeeman atomic absorption spectrometry
technique was used to quantitate the aluminium present
in high molecular mass and low molecular mass frac-
tions in relation to total aluminium present in original
and spiked serum.
Calibration standards
Calibration of the column was performed using the following stan-
dards: blue dextran (Afr = 2000000), γ-globulin (Mr = 150000),
albumin (MT = 69 000), ovalbumin (MT = 45 000), trypsin inhibitor
(Mr =24000), ribonuclease (Mr =13500), and tyrosine (Mr
= 180), at a concentration of 0.005 g/1. The flow rate was 0.3
ml/min.
Materials and Methods
Size exclusion chromatography
Gel filtration using Sephadex
Gel filtration of serum was performed on a Pharmacia column, 20
mm ID X 400 mm (Pharmacia Fine Chemicals, Uppsala, Sweden).
The column was packed with Sephadex G-100 SF (Sigma Chemi-
cal Company No G-100-50) according to the manufacturer's speci-
fication.
The column eluent buffer was 0.1 mol/1 sodium dihydrogen phos-
phate, 0.2 mol/1 sodium chloride, 0.5 g/1 sodium azide (Analar,
BDH Chemicals, Poole, England), adjusted to pH 7.4 at 25 °C and
filtered through a GV 0.22 μιη membrane (Millipore No.
GVWP04700). Flow rate was maintained with a peristaltic pump
(LKB Bromma 12000 Varioperpex, 220V 50H). The eluent frac-
tions were collected into aluminium-free polypropylene tubes
(Sterilin #144AS) using an automated fraction collector placed in
a climate chamber at 4 °C (LKB Bromma 7000 Ultrorac).
Calibration standards
The column void volume (V0) was determined by using blue
dextran 2000 (Pharmacia) and was found to be 9.5 ml at a flow
rate of 0.1 ml/min. Calibration of the column was performed using
either Pharmacia or Sigma (Sigma, St. Louis, MO, USA) standards,
at a concentration of 0.010 g/1. Standards used were as follows:
ribonuclease [relative molecular mass (Mr) = 13500], ovalbumin
(MT = 45 000), albumin (Mr = 69 000). A total of 0.5 mg of each
standard was loaded onto the column, representing a final loaded
concentration of 1.5 mg protein mixture.
Serum specimens
Sera were derived from blood drawn from occupationally exposed
volunteers working in potrooms of a primary aluminium smelter.
Control sera were obtained from subjects, none of whom had ever
worked in the aluminium industry. Volunteers known to be using
aluminium-containing medication were excluded from the study.
Serum samples were diluted 1 : 1 with eluent buffer and filtered
through a 0.8 μηι filter (Millex-PF Millipore). A serum volume of
0.5 ml was applied to the gel bed and elution was performed at a
flow rate of 0.1 ml/min. After elution of the void volume, collec-
tion of the fractions was started. A total of 424 fractions of 1 ml
each were collected per run into polypropylene tubes at 4 °C.
Fractions obtained from both the calibration and the serum elutions
were read on a Beckman DU Series 70 spectrophotometer at a
wavelength of 280 nm to identify the protein fractions.
The fractions from the serum elution were stored at 4 °C prior to
concentration and analysis of aluminium content.
High performance liquid chromatography (HPLC)
A high performance liquid chromatography system was used. This
consisted of a Spectra Physics-SP 8100 liquid Chromatograph
equipped with SP 8110 autosampler; HP 1040A diode-array detec-
tor with ChemStation Software (Hewlett Packard Company) and a
LKB 2113 Redirac fraction collector.
Size exclusion chromatography was performed using the gel per-
meation column TSK G4000 SW, 7.5 mm ID X 600 mm (Toso-
haas, Japan). The mobile phase was the same phosphate buffer
used for the Sephadex gel filtration.
Serum specimens
Serum samples were filtered through a 0.8 μηι filter and various
volumes (50—200 μΐ) were loaded onto the column to obtain pro-
tein profiles. Thirty six fractions, of 1 ml volume, were collected
for each run. The total nm time for a flow of 0.3 ml/min was 120
min. Fractions were stored at 4 °C until analysed.
Ultrafiltration method
For ultrafiltration, original control sera and sera from occupa-
tionally exposed probands were used. To establish the aluminium
distribution in serum at high aluminium load, aliquots of control
sera and sera from exposed subjects were spiked with aluminium
by adding 400 μ^ of Al to each sample and incubated at 37 °C
for 45 min before the ultrafiltration procedure. The 1000 mg/1 AI
standard in 0.1 mol/1 HC1O4 (Hopkins and Williams Ltd., Essex,
England) was used to prepare the working standard of l mg/1 AI
for spiking, which was adjusted to pH 7.4 with sodium hydroxide
solution prior to use.
Separation of serum into high molecular mass and low molecular
mass fractions was performed using Centricon concentrators (Ami-
con Inc.) having a nominal cut-off of Mr = 10000.
Aliquots of serum (1 ml) were centrifuged in a fixed-angle rotor
(Sorvall RC-2B centrifuge) at 5000 g-force for 1 hour at 4 °C. The
retentates and filtrates obtained for each serum sample were ana-
lysed for aluminium content.
Preconcentration of protein fractions
Due to the low concentrations of aluminium present in serum
following the fractionation, some of the protein fractions were pre-
concentrated using precipitation with ice-cold acetone before
analysis.
Atomic absorption spectroscopy
A Perkin-Elmer Model 4100L atomic absorption spectrometer with
Zeeman-Effect background correction equipped with a transversely
heated graphite atomizer was used for the determination of alumin-
ium in serum, eluent, and protein retentates and filtrates after ultra-
filtration.
The instrument settings and furnace programmes for analysis of
aluminium in serum have been described previously (7). Our con-
ditions differ from those published by Bradley and Leung, particul-
arly in the drying and ashing stages, both for temperatures and
times used (23). We used multiple drying stages and extended dry-
ing times to ensure the complete drying of the specimen prior to
the ashing steps.
A calibration curve was constructed by the method of addition and
was found to be linear up to 64 μg/l of Al. Samples and standards
were diluted with magnesium matrix modifier (5.46 mmol/1
Mg(NO3)2 in 1 g/1 Triton X-100) using the AS-70 autosampler on
the spectrophotometer. For the determination of aluminium in the
eluent, and protein retentates and filtrates, the procedure was modi-
fied to compensate for the matrix changes due to the presence of
buffers. We found that to obtain optimal atomization, the temper-
ature at the second stage of ashing had to be increased to 2000 °C,
as opposed to 1400 °C, for serum.
Quality control
Accuracy of analysis was assessed by including quality control
samples from Nycomed Seronorm™ Trace Elements (Oslo, Nor-
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way, batch 108) with each batch analysed. In addition, European
Pharmacopoeia Commission BRP human albumin was analysed
periodically.
Contamination precautions
To obtain reliable data throughout the entire study extremely strin-
gent precautions were applied at all stages of sample manipulation.
These were:
a) use of ultrapure water (Millipore > 16 ΜΩ · cm resistivity) for
all dilutions and washing procedures,
b) use of high-purity chemicals,
c) use of polypropylene vessels and tubes,
d) soaking of all the containers in 50% nitric acid, overnight,
e) continuous screening of all materials and reagents for possible
sources of metal contamination,
f) equilibrating of columns until aluminium free.
Blank readings were performed with each individual preparation.
In addition, all preparations were performed in a laminar flow
Class 1 cabinet and analysed under clean-room conditions.
Statistics
The ANOVA test was used for normally distributed data. The
Kruskal-Wallis test (Mann-Whitney or Wilcoxon two sample test)
was used for non-parametric data.
Results
Serum protein and aluminium profile
following Sephadex G-100 SF gel filtration
The elution pattern of all sera on the Sephadex G-100
SF showed nine major reproducible peaks. The first alu-
minium peak co-eluted with protein in fractions 12 to
23 (Mr between 100000 and 69000). The next fraction
with detectable aluminium, but no protein, was fraction
68. The next major aluminium peaks eluted in fractions
382 to 424 (Mr less than 10000) (fig. 1). All other de-
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Fig. 1 Serum protein and aluminium profile following Sephadex
G-100 SF gel filtration.
—· Protein markers: A = blue dextran; Β = albumin;
C = ovalbumin; D = ribonuclease
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Fig. 2 Serum protein and aluminium profile following HPLC.
A Aluminium
MT Molecular mass markers.
tected serum protein peaks did not contain detectable
aluminium, even after preconcentration of fractions.
Serum protein and aluminium profile
following HPLC
In order to preserve the natural distribution of alumin-
ium in serum, 0.1 mol/1 phosphate buffer, pH 7.4 was
used as the mobile phase. As a result, the elution peaks
obtained are tailed, indicating that the conditions used
were not optimal (fig. 2).
The elution profiles obtained did not differ for normal,
exposed and spiked sera. The presence of aluminium
was detected in fractions 13 to 15, followed by fractions
18 to 21. The ultrafiltrable aluminium complex was de-
tected in fractions 26 to 35.
Ultrafiltration
HPLC serum profile following ultrafiltration
The same serum samples (control and exposed) which
were fractionated using the HPLC technique were sub-
mitted to ultrafiltration, after which both retentate and
filtrate fractions obtained were re-fractionated using
HPLC (fig. 3). The peaks obtained for the retentates and
filtrates were found to be clearly defined, with the elu-
tion times corresponding to those obtained for the initial
sera, prior to ultrafiltration.
Distribution of aluminium (μg/l) in serum following
ultrafiltration
Absolute quantisation of aluminium using the Zeeman
atomic absorption spectrometry technique was per-
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Fig. 3 HPLC serum profile following ultrafiltration.
Retentate (Mr > 10000)
— Filtrate (Mr< 10000).
formed throughout the experimental procedure. The re-
sults presented in table 1 are a summary of a number of
different experiments. The total aluminium in all serum
samples was quantitated prior to the procedure of ultra-
filtration. Given that the average aluminium concentra-
tions in control serum samples are very low (4.76
± 1.63 μg/l), the concentrations of aluminium following
ultrafiltration would be difficult to quantitate accurately
(7). For this reason control serum samples with the high-
est aluminium concentrations were chosen in this ex-
periment; the fact that the aluminium concentrations in
the control sera are higher than those in the exposed sera
should not be given a clinical interpretation. Throughout
all experiments the recovery obtained after ultrafiltration
was good; in all cases the volume ratios of filtrates to
retentates were approximately 2:1. Additional serum
samples, from both control and exposed subjects, were
spiked with aluminium to confirm the trend in the alu-
minium distribution.
Figure 4 shows the proportional aluminium binding to
high molecular mass and low molecular mass serum
moieties, for original and spiked sera. For the purposes
of statistical analysis, the proportional aluminium bind-
ing is expressed also as a percentage of the total serum
aluminium.
Discussion
In order to ascertain the distribution of aluminium in
normal and occupationally exposed sera we applied two
different size exclusion Chromatographie techniques and
an ultrafiltration method.
Care was taken to maintain the physiological conditions
of sera by performing elutions at pH 7.4 using a phos-
phate buffer. Profiling of sera on Sephadex G-100 SF
ensured that the high molecular mass proteins with Μτ
> 100000 were eluted in the void volume. The remain-
Tab. 1 Distribution of aluminium ^ g/l) in serum following ultrafiltration.
Sera from
Control subjects
(n = 3)
Exposed subjects
(n = 3)
Control subjects, spiked
(n = 4)
Exposed subjects, spiked
(n = 5)
Total
aluminium
14.33
14.15
10.38
10.19
8.64
8.21
413.30
386.10
386.55
382.00*
438.30
416.50
413.20
407.42*
405.87*
Bound as
low molecular
mass complexes
MT < 10000
2.34
2.80
2.43
1.40
0.85
0.54
4.95
5.16
3.60
3.10
5.27
4.41
8.84
9.24
6.10
Bound as
high molecular
mass complexes
Μτ> 10000
12.15
12.00
7.40
10.00
10.50
8.10
333.20
360.00
407.00
429.60
425.69
394.32
405.32
396.23
420.23
Sum
14.49
14.80
9.83
11.40
11.35
8.64
338.15
365.16
410.60
432.70
430.96
398.73
414.16
405.47
426.33
Recovery
(%)
101.12
104.59
94.70
100.14 ±
111.87
131.37
105.24
116.16 ±
81.82
94.58
106.22
113.30
98.98 ±
98.33
95.73
100.23
99.52
105.04
99.77 ±
5.0
13.6
13.8
3.4
* Additional serum samples, from both control and exposed subjects, were spiked with aluminium to
confirm the trend in aluminium distribution.
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n = 4 n = 5
0.00
Low Mr%
High Mr%
Controls
19.6 ± 3.6
79.1 ± 7.0
Exposed
8.7 ± 3.2
91 .3 ±3.3
Control, spiked
1.1 ±0.4
98.9 ± 0.4
Exposed, spiked
1.6 ±0.5
98.4 ± 0.5
Fig. 4 Proportional aluminium binding to high and low MT li-
gands in serum fractions. The differences between original sera
from control subjects and exposed subjects were significant for
both low Mr (p < 0.004) and high Mr (p < 0.026) fractions. After
spiking, the differences in aluminium distribution were not statis-
tically significant.
Low MT% (High Mr%) = percentage of Al bound as low (high)
molecular mass complexes.
Controls = sera from control subjects.
Exposed = sera from ΑΙ-exposed subjects.
ing serum components were
into nine distinctive peaks.
subsequently separated
Detection of aluminium in all collected fractions re-
vealed that aluminium co-eluted with the protein peak
in fractions 12 to 23, which corresponds to proteins with
Mr < 100 000 but > 69 000. We deduced that these frac-
tions contained mainly transferrin-aluminium com-
plexes. Aluminium was also detected in fraction 68
which eluted shortly before the corresponding albumin
peak of the calibration standards. Until fraction 382 no
aluminium was detected. Once the retention time
reached the components with Mr < 13500, aluminium
was again present in fractions 382 to 424. The protein
and aluminium profiles in serum obtained by this
method are shown in figure 1. Although the separation
of serum components was very satisfactory and the pro-
files obtained were reproducible using this technique,
the procedure was tedious and time consuming.
An HPLC system equipped with a size exclusion TSK
column was subsequently used to separate serum com-
ponents. Separation obtained by HPLC was less than
ideal. The eluent used was a phosphate buffer at pH 7.4
to mimick physiological conditions and to minimise any
artificial changes in the distribution of aluminium
among serum components. Hence, optimal conditions of
separation were not achieved.
A typical profile obtained by this method is shown in
figure 2. Aluminium co-eluted in fractions 13 to 15 and
18 to 21, representing high molecular mass serum pro-
teins, and fraction 26 to 35 representing ultrafiltrable
low molecular mass serum components, not necessarily
proteins. Reproducible elution profiles were obtained for
repeated sample injections and as in the Sephadex sepa-
rations, these profiles did not differ for the different sera
analysed. This is in agreement with Favarato et al., who
profiled sera from normal and exposed subjects, and
found no differences in their protein profiles (24).
Furthermore, in our experiments with the Sephadex and
TSK columns, we observed no binding of aluminium to
the respective gel matrices. In all the profiles, alumin-
ium was only detected in the aforementioned protein
fractions, and these results were reproducible for a
number of different elutions.
To obtain a more accurate molecular mass speciation,
we subjected the same sera to ultrafiltration by using
Centricon concentrators having nominal cut-offs of Mr
= 10000. Figure 3 shows a typical profile with clearly
defined peaks for retentate and filtrate following HPLC.
In all cases, the elution times for these fractions corre-
sponded to those obtained for the initial non-ultrafil-
trated sera.
The distribution of aluminium between high molecular
mass and low molecular mass serum fractions in relation
to the total amount of aluminium present in different
original and spiked sera was also investigated. In the
spiking procedure we took extreme care to avoid dis-
turbing equilibria: the pH of the aluminium standard so-
lution was adjusted to pH 7.4 using a sodium hydroxide
solution and the standard was prepared daily and filtered
through 0.22 μηι membranes before use. The "back-
ground" aluminium was carefully monitored and
subtracted from all the readings.
The total aluminium was quantitated prior to the pro-
cedure of ultrafiltration. Following ultrafiltration, the re-
covery for the sum of high molecular mass and low mo-
lecular mass fractions was calculated. The average re-
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covery for control sera, before and after spiking, was
100.14 ± 5.0% and 98.98 ± 13.8%, respectively. The
average recovery for sera from exposed subjects, before
and after spiking, was 116.16 ± 13.6% and 99.7
± 3.4%, respectively. The overall mean recovery was
102.91 ± 11.0%, which is very satisfactory.
Speciation of aluminium between high molecular mass
and low molecular mass serum fractions after ultrafiltra-
tion, expressed as a percentage of the total aluminium
present in the original serum, showed that in controls,
19.6 ± 3.6% of aluminium was bound to low molecular
mass fractions with the remaining 79.1 ± 7.0% binding
to high molecular mass fractions. In serum of exposed
workers this distribution differed, with only 8.7 ± 3.2%
binding to low molecular mass fractions and 91.3
± 3.3% to high molecular mass fractions. The differ-
ences between control and exposed sera were found to
be significant for both low molecular mass (p < 0.004)
and high molecular mass (p < 0.026). After spiking con-
trol and exposed sera with 400 g/l of Al, this distribu-
tion changed noticeably. In the case of control sera, only
1.12 ± 0.4% of aluminium was bound to low molecular
mass fractions and 98.88 ± 0.4% bound to high molecu-
lar mass fractions. In exposed sera, 1.6 ± 0.5% was
bound to low molecular mass fractions, with the remain-
ing 98.4 ± 0.5% binding to high molecular mass protein
complexes. These changes in aluminium distribution
were found to be not significant due to the small sample
size and the difference in variance between the two sam-
ples. This redistribution of aluminium in serum, when
the aluminium concentration is high, is comparable to
that observed by Favarato et al. (24).
Our results are in direct conflict with those obtained by
Wrobel et al., who found that the percentage of ultra-
filtrable aluminium did not change with increasing con-
centration of aluminium. They found that, when the total
aluminium increased, the aluminium content bound to
the low molecular mass fraction increased in the same
proportion (20). In our study, it appears that the percen-
tage of low molecular mass aluminium complexes
decreased with an increase in total aluminium content.
These differences may be attributed to the different cut-
off membranes used in both studies (Mr = 30 000 used
in the former). On the other hand, in our study, the abso-
lute quantity of aluminium available for circulation, in
spiked sera, was much higher than that found in original
serum samples. Furthermore, in our study we used sera
from healthy occupationally exposed subjects, as
opposed to uraemic subjects.
We obtained acceptable separation of serum components
and identification of aluminium binding sites by two
size exclusion Chromatographie methods. The profiles
obtained for all the sera analysed were very similar and
no displacement of aluminium between different frac-
tions was observed. In addition, there was no transfer of
aluminium between serum samples and column packing
materials. Background contamination levels for eluent
and column matrices were controlled and minimised by
following the procedures described previously in the
methodology section. Spiking of the sera with 400 g/l
of Al at a controlled pH did not produce saturation ef-
fects and aluminium was detected only in specific frac-
tions. Prior to deciding on the concentration of alumin-
ium to be used in the spiking experiments, we worked
with serum samples obtained from uraemic patients,
containing, on average, 390 g/l of Al.
The ultrafiltration technique proved to be the method of
choice for the quantitative recovery studies, for both
original and spiked sera, without dilution effects which
are inherent to Sephadex and HPLC separations.
Conclusion
In our present study the distribution of aluminium be-
tween high molecular mass and low molecular mass se-
rum complexes in original sera from exposed subjects
differed from that observed in control sera. More alu-
minium was present in high molecular mass fractions in
exposed subjects than in controls having similar total
aluminium content. This confirms that high molecular
mass proteins, transferrin being the main protein carrier
of aluminium, have an ability to bind aluminium in
blood. Initially, this binding of aluminium to transferrin
may have detoxifying effects, though the final deposi-
tion of the aluminium remains the source of concern
(25). After the addition of a high concentration of alu-
minium (400 g/l of Al) to sera from occupationally
exposed subjects, more aluminium was bound to high
molecular mass fractions, with only 1.6% of aluminium
being bound to the low molecular mass species. How-
ever, this aluminium percentage represents an increased
absolute aluminium quantity in the circulation. This is
of particular importance in the industrial setting, since
ultrafiltrable aluminium complexes (fluoride, silicic acid
and citrate) are thought to play a major role in the bio-
availability and excretion of aluminium.
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